Urso Capsules 250Mg (1 Box = 1 Strip)(1 Strip = 10 Capsules)

During the first 3 months of treatment, liver function parameters ASAT (SGOT), ALAT (SGPT) and ?-GT is advised to be monitored by the physician every 4 weeks, thereafter every 3 months. Apart from allowing for identification of responders and non-responders in patients being treated for primary biliary cirrhosis, this monitoring would also enable early detection of potential hepatic deterioration, particularly in patients with late stage primary biliary cirrhosis.
In order to assess therapeutic progress and for timely detection of any calcification of the gallstones, depending on stone size, the gall bladder is advised to be visualised (oral cholecystography) with overview and occlusion views in standing and supine positions (ultrasound control) 6-10 months after the beginning of treatment.
If the gall bladder cannot be visualised on X-ray images, or in cases of calcified gallstones, impaired contractility of the gall bladder or frequent episodes of biliary colic, Ursodeoxycholic acid is advised to not be used.